Alesse Birth Control Pills: Clinical Overview
Alesse (levonorgestrel 100 mcg/ethinyl estradiol 20 mcg) is a low-dose combined oral contraceptive indicated for pregnancy prevention with a typical-use failure rate of approximately 5% and perfect-use failure rate of 0.1%, demonstrating effective contraception with acceptable cycle control and tolerability. 1
Primary Indication
Alesse is indicated for the prevention of pregnancy in women of reproductive age. The formulation contains 100 mcg levonorgestrel and 20 mcg ethinyl estradiol, making it one of the lowest-dose combined hormonal contraceptives available 1, 2.
Efficacy Data
- Perfect use: 0.1% failure rate (1 in 1000 women)
- Typical use: 5% failure rate (5 in 100 women) 1
- Clinical trials demonstrated a Pearl Index of 0.84-0.88 across 26,554-27,011 cycles 2, 3
- The cumulative pregnancy rate after 6 cycles was 0.41% per woman 3
Dosing Schedule
- Take one active pill daily for 21 consecutive days
- Follow with 7 days of placebo pills (or no pills)
- Start new pack immediately after hormone-free interval
Initiation Timing
Quick-start method is recommended 4, 5:
- Can be started any time if reasonably certain the patient is not pregnant
- If started within first 5 days of menstrual bleeding: No backup contraception needed
- If started >5 days after bleeding started: Use backup contraception (condoms or abstinence) for 7 consecutive days 4
Special Populations
Postpartum (breastfeeding) 4:
- Do NOT use during first 3 weeks postpartum (U.S. MEC 4) - increased VTE risk
- Generally should NOT use during week 4 postpartum (U.S. MEC 3) - potential effects on breastfeeding
- Can consider after 6 weeks postpartum if no other VTE risk factors
Postpartum (non-breastfeeding): Can start at 3 weeks postpartum
Absolute Contraindications
Do NOT prescribe Alesse if patient has 1:
- Known or suspected pregnancy
- Known or suspected breast carcinoma
- Undiagnosed abnormal genital bleeding
- Hypersensitivity to any component
- Benign or malignant liver tumors
- Acute liver disease
- Severe uncontrolled hypertension (≥160/100 mmHg)
- Migraines with aura or focal neurologic symptoms
- Thromboembolism or thrombophilia
- Complicated valvular heart disease
- Diabetes with vascular complications
- Complicated solid organ transplantation 6
Important Precautions
Smoking is NOT a contraindication in women <35 years old 6, though should be discouraged.
VTE risk: Increases from 1 per 10,000 to 3-4 per 10,000 woman-years with COC use (compared to 10-20 per 10,000 during pregnancy/postpartum) 6.
Managing Missed Pills
One Pill Late (<24 hours) 4:
- Take the late pill as soon as possible
- Continue remaining pills at usual time
- No backup contraception needed
- Emergency contraception usually not needed
One Pill Missed (24 to <48 hours) 4:
- Take the most recent missed pill immediately (discard other missed pills)
- Continue remaining pills at usual time (may take 2 pills same day)
- Use backup contraception for 7 consecutive days
- If pills missed in last week of active pills (days 15-21): Skip hormone-free interval, start new pack immediately
- Consider emergency contraception if missed pills were in first week AND unprotected intercourse occurred in previous 5 days
Two or More Pills Missed (≥48 hours) 4:
- Same instructions as one missed pill
- Backup contraception for 7 days is critical
- If in last week: Skip placebo week, start new pack
- Emergency contraception should be strongly considered if first-week miss with recent intercourse
Managing Vomiting/Diarrhea
Within 24 hours of taking pill 4:
- No need to redose
- Continue pills at usual time
- No backup contraception needed
Continuing 24 to <48 hours 4:
- Continue pills at usual time
- Use backup contraception until 7 consecutive pills taken after symptoms resolve
- If occurred in last week of active pills: Skip hormone-free interval
- Consider emergency contraception if occurred in first week with recent unprotected intercourse
Continuing ≥48 hours 4:
- Same management as 24-48 hours
- Backup contraception for 7 days after resolution is essential
Common Side Effects and Management
Most common adverse effects 2, 3:
- Headache (14% of users) - most common reason for discontinuation (2%)
- Metrorrhagia/breakthrough bleeding (8%) - second most common discontinuation reason (2%)
- Nausea (4.1%)
- Breast tenderness
- Breakthrough bleeding (with/without spotting): 12.9% of cycles
- Spotting alone: 10.1% of cycles
- Amenorrhea: 2.6% of cycles
- Bleeding irregularities generally improve over time and are not harmful 4
Managing Breakthrough Bleeding on Extended Regimens
If using extended/continuous regimens 4, 7:
- Hormone-free interval of 3-4 consecutive days can improve bleeding
- NOT recommended during first 21 days of extended use
- NOT recommended more than once per month (reduces contraceptive effectiveness)
- NSAIDs for 5-7 days may help with spotting
Non-Contraceptive Benefits
- No negative effect on long-term fertility - completely reversible 6
- Protection against endometrial and ovarian cancers with >3 years use 6
- No increased risk of breast cancer 6
- Can be used for extended/continuous regimens to minimize menstrual-related symptoms 5
Emergency Contraception Use
Alesse can be used for emergency contraception 1:
- Dose: 5 pink pills taken within 72 hours of unprotected intercourse
- Second dose of 5 pills taken 12 hours after first dose
- Reduces pregnancy risk by at least 75%
Clinical Pearls
Cycle control advantage: Studies demonstrate superior cycle control with levonorgestrel-containing formulations compared to norethindrone-containing 20 mcg pills, with significantly lower rates of intermenstrual bleeding (29% vs 62.9% in cycle 3) 8.
Extended regimens: Can be used continuously or in extended cycles to reduce menstrual frequency, particularly beneficial for adolescents who frequently miss pills 5.
No pelvic exam required: Gynecologic examination is NOT needed to determine eligibility for COC use 6.
Prescribing duration: CDC recommends prescribing up to 1 year of COCs at one time 6.
Follow-up: Routine visit 1-3 months after initiation is useful for addressing adverse effects or adherence issues 6.